CMVLF (Cellectis) Quality Rank


CMVLF Cellectis SA CMVLF
60 GF Score
Price $3.47
GF Value $3.87
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Cellectis Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Cellectis Quality Rank Related Terms

CMVLF
60GF Score
Cellectis SA CMVLF
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cellectis (CMVLF) Overvalued in 2026?

Based on GuruFocus' analysis, Cellectis stock appears to be undervalued. The current stock price of $3.47 is trading 10.3% below its estimated GF Value™ of $3.87. GuruFocus considers Cellectis to be Modestly Undervalued.

Key valuation signals for CMVLF:

  • Quality Rank:
  • GF Value™: $3.87 vs. price of $3.47 (10.3% below fair value)
  • GF Score™: 60/100 with 4 warning signs

No single metric tells the full story. See the CMVLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cellectis Business Description

Address 8, rue de la Croix Jarry, Paris, FRA, 75013
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
60GF Score

Get the complete analysis for CMVLF

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.47
Price
$3.87
GF Value